Abstract
The aim of this study is to evaluate the relationship between the aspartate aminotransaminase (AST) and alanine aminotransaminase (ALT) ratio and local disease control in patients with head and neck squamous cell carcinomas (HNSCC) treated with radiotherapy/chemoradiotherapy. We calculated the pre-treatment AST/ALT ratio in 670 patients with HNSCC treated with radiotherapy (n= 309, 46.1%) or chemoradiotherapy (n= 361, 53.9%). Five-year local recurrence-free survival for patients with a low AST/ALT ratio value (n= 529, 79.0%) was 75.0% (95% CI: 71.1-78.9), and for patients with a high value (n= 141, 21.0%) it was 53.4% (CI 95: 44.4-62.4) (p= 0.0001). In a multivariable analysis, patients with a high ratio had nearly twice the risk of having a local tumor recurrence (HR 1.97, 95% CI 1.42-2.75, p= 0.0001). The AST/ALT ratio was independently associated with the risk of local recurrence in patients with HNSCC treated with radiotherapy or chemoradiotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
